Should men with Lynch syndrome be screened for prostate cancer?
First results from the international IMPACT study suggest two pathogenic gene variants put carriers at increased risk
Men with two mismatch repair gene mutations seen in Lynch syndrome may be at increased risk of prostate cancer and could benefit from PSA screening, researchers suggest.
Replication of the findings in further annual rounds of PSA testing in the IMPACT (identification of men with a genetic predisposition to prostate cancer) study would be needed, however, before screening can be recommended, they caution.
The cohort, aged between 40 and 69 comprises 962 men (93% white, mean age 53) from eight countries, including Australia, recruited between 2012 and 2020, 644 of whom (67%) carry a mismatch repair gene pathogenic variant.
The MLH1 variant was present in 204 participants, 305 had an MSH2 variant and 135 had an MSH6 variant.
